Critical Pharmacodynamic Warning
halothane affects the 2E1 metabolic pathway.
When patients take halothane concurrently with drugs metabolized by 2E1, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.
Clinical Impact: As a strong inhibitor , halothane can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.
Clinical Overview for halothane
This page outlines known interaction pathways involving halothane, focusing primarily on its profile as a Strong inhibitor affecting the 2E1 pathway.
Enzyme Interaction Profile
halothane demonstrates strong inhibitor potency against 2E1. Clinical significance of this interaction requires further evaluation.
Inhibitor
A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.
Clinical Example: halothane affects 2E1Inducer
A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.
Known Inducers: isoniazidInteraction Details
| Drug Name | halothane |
| Affected Enzyme | 2E1 |
| Inhibitor Strength | Strong inhibitor Unknown |
| Inducers | isoniazid |
| Inhibitors | disulfiram |
Clinical Recommendations
Consult primary literature for guidance.
- Therapeutic drug levels
- Adverse effect monitoring
- Clinical response assessment
- Consider dose reduction
- Evaluate alternative therapies
- Adjust based on response
Quick Facts
3602
2E1
Enzyme Inhibition
Unknown
Clinical Significance
Clinical significance requires further evaluation.
Information Sources
- FDA Drug Interaction Database
- Clinical Pharmacology Guidelines
- Pharmaceutical Labeling Information
- Published Clinical Studies
Last updated: June 12, 2026